ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Urgent FDA Action Turns Power Morcellation Into Rarely Used Gynecological Procedure

December 5, 2014

Program Announcement For Clinical Research

February 29, 1980

“National Clearinghouse” To Guide Selection, Testing, Evaluating Of Suspected Carcinogens

April 9, 1976

AACR Presents Awards at Annual Meeting

April 5, 2013

Senate Bill Includes $10 Billion for NIH

February 6, 2009

Mysterious Group Urges Letters In Support Of Fisher, Calls For Investigation of NCI

April 22, 1994